WaveMan
WaveMan · Company
GLSI · Greenwich Lifesciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

GLSI Greenwich LifeSciences (GLSI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001799788
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
33
13F, latest reported quarter

What the filings say about GLSI

Insiders, 180 days
+$97.0K net bought
1 buyer

Greenwich LifeSciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Greenwich LifeSciences, Inc. insiders bought a net $97.0K of stock across 109 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Patel Snehal
CEO and CFO
BUY
2026-07-30 SECtraded 2026-07-29
700
$9.2K
+26.9%
Context
  • 82 earlier Form 4 trades (code P or S) here by this insider (82 buys), the last on Jul 28, 2026.
  • -1.6% median (+21.0% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 5,611,402 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO Patel Snehal bought about $9.2K of GLSI on Jul 29, 2026; 33 funds added in the latest 13F quarter.
Patel Snehal
CEO and CFO
BUY
2026-07-30 SECtraded 2026-07-28
1,500
$20.4K
+26.9%
Context
  • 81 earlier Form 4 trades (code P or S) here by this insider (81 buys), the last on Jul 27, 2026.
  • -3.6% median (+19.6% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 5,610,702 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO Patel Snehal bought about $20.4K of GLSI on Jul 28, 2026; 33 funds added in the latest 13F quarter.
Patel Snehal
CEO and CFO
BUY
2026-07-29 SECtraded 2026-07-27
1,500
$20.4K
+22.1%
Context
  • 80 earlier Form 4 trades (code P or S) here by this insider (80 buys), the last on Jul 24, 2026.
  • -3.6% median (+19.1% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 5,609,202 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO Patel Snehal bought about $20.4K of GLSI on Jul 27, 2026; 33 funds added in the latest 13F quarter.
Patel Snehal
CEO and CFO
BUY
2026-07-27 SECtraded 2026-07-24
1,100
$14.2K
+27.3%
Context
  • 79 earlier Form 4 trades (code P or S) here by this insider (79 buys), the last on Jul 23, 2026.
  • -3.6% median (+18.7% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 5,607,702 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO Patel Snehal bought about $14.2K of GLSI on Jul 24, 2026; 33 funds added in the latest 13F quarter.
Patel Snehal
CEO and CFO
BUY
2026-07-27 SECtraded 2026-07-23
2,500
$32.9K
+27.3%
Context
  • 78 earlier Form 4 trades (code P or S) here by this insider (78 buys), the last on Jan 13, 2026.
  • -3.6% median (+18.8% mean) 90-day return after 30 previous buys.
  • The trade is 0.0% of the 5,606,602 shares held after it.
  • No other insider bought within 30 days.
  • 33 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CEO and CFO Patel Snehal bought about $32.9K of GLSI on Jul 23, 2026; 33 funds added in the latest 13F quarter.
109 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 104 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$97.0K over 180 days
+$9.2K over 90 days · +$97.0K of it by a 10%+ holder
more than 76% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
33 funds bought in last quarter
below 61% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
20.7% of the float short (float per yahoo 2026-10-26) · 11.4 days to cover · settled 2026-09-30
more than 74% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch GLSI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+86.3%12M
-15%+79%+172%+265%2025-102025-122026-022026-042026-062026-082026-10 2025-12-31 · Patel Snehal bought $91.8K2025-11-07 · Patel Snehal bought $89.4K2026-01-12 · Patel Snehal bought $79.9K2025-12-30 · Patel Snehal bought $63.0K2026-01-13 · Patel Snehal bought $53.7K2025-12-18 · Patel Snehal bought $51.7K2025-11-25 · Patel Snehal bought $38.5K2026-07-23 · Patel Snehal bought $32.9K2025-10-31 · Patel Snehal bought $21.3K2026-07-27 · Patel Snehal bought $20.4K2026-07-28 · Patel Snehal bought $20.4K2026-07-24 · Patel Snehal bought $14.2K2026-07-29 · Patel Snehal bought $9.2K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns GLSI: institutional holders (13F)

13F holdings, latest reported quarter
BlackRock, Inc.
485,854 sh
$11.4M
VANGUARD CAPITAL MANAGEMENT LLC
278,190 sh
$6.5M
GEODE CAPITAL MANAGEMENT, LLC
168,179 sh
$3.9M
STATE STREET CORP
143,086 sh
$3.4M
VANGUARD PORTFOLIO MANAGEMENT LLC
80,861 sh
$1.9M

Congress trades in GLSI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

GLSI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

GLSI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
MFS Blended Research Small Cap Equity Portfolio
$71.1K position · as of 2026-06-30
0.1%
Franklin Small Cap Enhanced ETF
$102.1K position · as of 2026-06-30
0.1%
MFS Blended Research Small Cap Equity Fund
$176.9K position · as of 2026-05-31
0.1%
VANGUARD U.S. MOMENTUM FACTOR ETF
$897.1K position · as of 2026-05-31
0.0%
iShares Micro-Cap ETF
$532.2K position · as of 2026-06-30
0.0%
Small Cap Core Fund
$105.6K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $97.0K bought by insiders over 180 days, 33 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

GLSI financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-1,208%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-374.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$19.4M-$17.6M-$9.3M-$8.0M
Net income-$19.4M-$17.4M-$8.9M-$7.8M
EPS (diluted)-1.43-1.34-0.69-0.61
Operating cash flow-$9.9M-$7.3M-$6.5M-$6.2M
Cash$6.2M$4.1M$7.0M$13.5M
Buybacksn/an/an/a$7.5M
SEC XBRL, fiscal years, as known on 2026-10-28

GLSI Stock Sonar score 4/7 axes

Find similar shapesCompare

GLSI ranks highest on insider conviction (66th percentile) and institutional and government (39th), and lowest on profitability (5th), among Pharma & Biotech peers.

Profitability
5
Inputs
  • Return on equity-1208% · 3 pct, sector of 545
  • Return on assets-374.5% · 6 pct, sector of 691
  • Return on invested capitalthe filed year and its quarters do not reconcile, so the trailing figure is withheld
  • Return on capital employedthe filed year and its quarters do not reconcile, so the trailing figure is withheld
Insider conviction
66
Inputs
  • Net Form 4 buying (codes P and S), 180d$97K · 76 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
39
Inputs
  • Funds adding, latest quarter33 · 39 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
14
Inputs
  • Short interest, % of float+20.7% · 14 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

GLSI filings, in plain words

Are Greenwich LifeSciences insiders buying or selling GLSI?

In the 180 days to 2026-10-28, Greenwich LifeSciences insiders were net buyers, a net $97.0K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Greenwich LifeSciences insiders were net buyers of GLSI, a net $97.0K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $97.0K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies